A post hoc analysis presented at CCR West found sarilumab outperformed adalimumab and placebo in HbA1c improvement in rheumatoid arthritis patients with diabetes.
Beni Toure
Advertisement
Articles by Beni Toure
The JAK inhibitor previously approved for rheumatoid arthritis has reported early primary endpoint outcomes in its ongoing phase 3 trial.
Advertisement
Latest Updated Articles
Baricitinib Hits 16-Week Marks for Atopic DermatitisAugust 24th 2019
For HbA1c in RA Patients, Sarilumab Outperforms Adalimumab, PlaceboSeptember 29th 2019
Advertisement
Advertisement
Trending on Rheumatology Live
1
Bimekizumab Beats Risankizumab on ACR50 in First IL-17A/F vs IL-23 Head-to-Head
2
Sonelokimab Reduces Inflammation, Osteoblastic Activity in Phase 2 Proof-of-Concept axSpA Study
3
OLINGUITO: Filgotinib Meets Phase 3 Primary Endpoint in r/nr-axSpA, With Xenofon Baraliakos, MD, PhD
4
Nipocalimab Demonstrates Proof of Concept for FcRn Blockade for SLE
5